Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sudo Biosciences ophthalmic TYK2 inhibitor
- Development stage
- Preclinical
- Lead developer
- Sudo Biosciences
- Modality
- Small Molecules
- Administration
- Ophthalmic, Topical
01
Overview
Sudo Biosciences is developing a topical small-molecule inhibitor of Tyrosine Kinase 2 (TYK2) specifically for the treatment of various ophthalmological conditions. The drug is designed to target the TYK2 pseudokinase domain (JH2), which allows for high selectivity over other Janus kinases (JAKs). By inhibiting TYK2, the molecule modulates cytokine signaling pathways (such as IL-12, IL-23, and Type I interferons) that are key drivers of immune-mediated inflammatory diseases. This program is currently in the preclinical discovery stage, and the company is actively seeking a partner for further development.
- Other names
- Ophthalmic candidateSudo Biosciences TYK2 ophthalmic program
02
Targets
TYK2 JH2 (Tyrosine kinase 2 Janus homology 2 pseudokinase domain)
Beyond the preview
Go deeper on Sudo Biosciences ophthalmic TYK2 inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sudo Biosciences ophthalmic TYK2 inhibitor.